1493P A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
| Autor: | Jankowski, T., Sótér, S., Raumlau, R., Chilingirova, N., Cholakova, M.D., Seidl, B., Moore, M., Joshi, R., Vitoc, V., Zaporojan, V., Gryaznov, S., Watkins, P., Obrocea, M. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S842-S842 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|